Related Experiment Video
Updated: May 9, 2026
09:44
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
Endothelin-1 gene polymorphism in sudden sensorineural hearing loss
Yasue Uchida1, Masaaki Teranishi, Naoki Nishio
1Department of Otorhinolaryngology, Aichi Medical University, Nagakute, Aichi, Japan; Department of Otorhinolaryngology, National Center for Geriatrics and Gerontology, Aichi, Japan.
The Laryngoscope
|July 9, 2013
Summary
The endothelin-1 gene's recessive genotype (rs5370) is linked to a higher risk of sudden sensorineural hearing loss (SSNHL). However, individuals with this genotype experienced less severe hearing loss compared to the wild-type.
Area of Science:
- Genetics
- Otolaryngology
- Molecular Biology
Background:
- Endothelin-1, a vasoconstrictor peptide, is present in auditory structures.
- Sudden sensorineural hearing loss (SSNHL) is an idiopathic condition affecting hearing.
- The Lys198Asn (G/T) polymorphism (rs5370) in the endothelin-1 gene is a potential factor in SSNHL.
Purpose of the Study:
- To investigate the association between the endothelin-1 gene Lys198Asn (rs5370) polymorphism and SSNHL.
- To analyze if this genetic variation influences the severity of SSNHL.
Main Methods:
- A case-control study comparing 72 SSNHL patients with 2,159 controls.
- Logistic regression analysis was used to determine odds ratios (ORs) for SSNHL risk.
- Audiometric pure-tone averages were assessed in relation to genotype in a subgroup of patients.
Main Results:
- The recessive genetic model showed a significant association between the endothelin-1 rs5370 polymorphism and increased SSNHL risk (adjusted OR: 2.173).
- No significant associations were found under additive or dominant models.
- Hearing loss severity differed significantly by genotype, with the GG genotype exhibiting greater mean pure-tone averages (78.6 dB) compared to GT (66.4 dB) and TT (57.8 dB).
Conclusions:
- The recessive genotype of the endothelin-1 Lys198Asn polymorphism is associated with a higher risk of SSNHL.
- Individuals with the recessive genotype may experience less severe hearing loss.
- Endothelin-1's role in the pathophysiology of SSNHL warrants further investigation.
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:33Pleiotropy
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...